Physician profile

George David Reeder

Pulmonary Disease · Salisbury, MD

NPI 1760472153

$1,986.61

in general payments reported to CMS, 2019-2025

18 companies · $323 in 2025

The $323 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).

See the full distribution for Pulmonary Disease

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$896.83
Education$98.99

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Astrazeneca Pharmaceuticals LP $312.04 2019-2023 Fasenra
Genzyme Corporation $296.92 2019-2025
Boehringer Ingelheim Pharmaceuticals, INC. $259.92 2019-2021
Glaxosmithkline, LLC. $195.14 2019-2025 Trelegy Ellipta, Arexvy, Nucala
Insmed, INC. $191.68 2019-2024 Arikayce
Amgen INC. $174.88 2022-2025 Tezspire
Sanofi-Aventis U.S. LLC $98.99 2025
Inspire Medical Systems, INC. $88.76 2025 Inspire
Novartis Pharmaceuticals Corporation $78.58 2022-2024
Grifols USA, LLC $61.10 2023-2024 Prolastin-C Liquid
Sunovion Pharmaceuticals INC. $54.97 2019
Pfizer INC. $46.88 2022-2024
Janssen Pharmaceuticals, INC $37.70 2021
Gilead Sciences, INC. $19.32 2023
Regeneron Healthcare Solutions, INC. $18.80 2022
Show all 18 companies
CompanyGeneral paymentsYearsTop products
Electromed, INC. $17.89 2024 Smartvest
Resmed Corp $16.77 2023
Tactile Systems Technology INC $16.27 2023 Entre Plus, Flexitouch Plus

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

George David Reeder

$1,986.61

in general payments reported 2019-2025

Years
2019-2025
Top company
Astrazeneca Pharmaceuticals LP
Context
The $323 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).

https://glasscript.com/doctor/307160/george-david-reeder

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Download CSV

The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.